Table 2 Baseline demographic and clinical characteristics by treatment, study and overall
ATTAIN | AUGMENT COPD | Pooled analysis sample | |||||
|---|---|---|---|---|---|---|---|
Characteristic | Aclidinium 400 μg (n = 269)a | Placebo (n = 273)a | Aclidinium 400 μg (n = 337)a | Placebo (n = 331)a | Aclidinium 400 μg (n = 583)b | Placebo (n = 578)b | All patients (n = 1161)b |
Age, years, mean (SD) | 62.9 (8.4) | 62.0 (8.0) | 64.4 (8.7) | 63.5 (8.9) | 63.7 (8.6) | 62.8 (8.5) | 63.2 (8.6) |
Male, n (%) | 182 (67.7) | 189 (69.2) | 188 (55.8) | 175 (52.9) | 356 (61.1) | 347 (60.0) | 703 (60.6) |
Caucasian, n (%) | 257 (95.5) | 260 (95.2) | 314 (93.2) | 316 (95.5) | 548 (94.0) | 552 (95.5) | 1100 (94.7) |
BMI, kg/m2, mean (SD) | 27.0 (4.8) | 26.6 (5.2) | 27.5 (5.3) | 27.7 (5.6) | 27.3 (5.1) | 27.2 (5.5) | 27.2 (5.3) |
Current smoker, n (%) | 148 (55.0) | 144 (52.8) | 171 (50.7) | 169 (51.1) | 303 (52.0) | 300 (51.9) | 603 (51.9) |
Smoking history, pack-years, mean (SD) | 41.7 (21.1) | 38.9 (18.3) | 52.0 (26.1) | 53.4 (28.5) | 47.1 (23.4) | 47.1 (25.8) | 47.1 (24.6) |
Post-bronchodilator FEV1, L, mean (SD)c | 1.6 (0.5) | 1.6 (0.5) | 1.5 (0.5) | 1.6 (0.5) | 1.6 (0.5) | 1.6 (0.5) | 1.6 (0.5) |
Post-bronchodilator FEV1, % predicted, mean (SD)c | 56.2 (12.2) | 56.6 (12.8) | 53.0 (13.3) | 52.6 (13.3) | 54.5 (12.9) | 54.2 (13.3) | 54.4 (13.1) |
% bronchial reversibility (SD) | 11.3 (12.9) | 12.3 (15.7) | 19.1 (16.5) | 18.4 (15.2) | 15.7 (15.6) | 15.7 (15.7) | 15.7 (15.6) |
Number of exacerbations in previous year, mean (SD) | 0.5 (0.7) | 0.4 (0.9) | 0.3 (0.8) | 0.3 (0.6) | 0.4 (0.8) | 0.3 (0.7) | 0.4 (0.8) |